Personalised medicine and population health: breast and ovarian cancer
- 873 Downloads
It has been suggested that a personalised approach to cancer prevention and screening might lead to a new paradigm for cancer control. Various aspects include testing for high-penetrance cancer susceptibility genes and generating personal risks scores, based on panels of single nucleotide polymorphisms. These tests can categorize women into various groupings of risk for cancer prevention (surgery and chemoprevention) cancer screening and prevention of cancer recurrence. In this review, I investigate various claims and come to the conclusion that the approach may be beneficial for the occasional patient but is unlikely to have any impact on reducing the burden of cancer incidence and mortality as whole. Challenges include meeting a high uptake of the test in the population, developing an effective and acceptable intervention and the willingness of healthy women to follow health care provider recommendations. The review focuses on strategies to reduce mortality from breast and ovarian cancer but is potentially applicable to other cancer sites, such as colon, prostate, and endometrial.
KeywordsPrecision medicine Personalised medicine Personal risk scores Cancer prevention Cancer screening
I thank Victoria Sopik for reviewing the manuscript before submission.
Compliance with ethical standards
Conflict of interest
The author declares that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
For this type of study, formal consent is not required.
- Burke W, Zimmern R (2007) Moving beyond ACCE. PHG Foundation, CambridgeGoogle Scholar
- Cancer Incidence in Five Continents (2002) IARC Scientific Publications, LyonGoogle Scholar
- CG001 Panel v2.3 HOTSPOT ANALYSIS [Internet]. Contextual Genomics, Vancouver (2016). http://contextualgenomics.com/wp-content/uploads/2016/02/CG001.v2.3_Cancer-Panel-1.pdf
- Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRefGoogle Scholar
- Le Tourneau C, Delord JP, Gonçalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334CrossRefGoogle Scholar
- Nelson HD, Cantor A, Humphrey L et al (2016) Screening for breast cancer: a systematic review to update. The 2009 U.S. Preventive Services Task Force Recommendation [Internet]. Agency for Healthcare Research and Quality, RockvilleGoogle Scholar
- Personalized Risk Stratification for Prevention and Early Detection of Breast Cancer [Internet]. Genome Canada (2018). https://www.genomecanada.ca/en/personalized-risk-stratification-prevention-and-early-detection-breast-cancer
- Reiner AS, John EM, Brooks JD et al (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 31:433–439CrossRefGoogle Scholar
- Stand Up To Cancer Canada—Canadian Breast Cancer Foundation Dream Team Is Announced, Just One Year After Inaugural Telecast [Internet]. Philadelphia (USA): American Association for Cancer Research (2015). http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=768#.VrUoSVMrJsN